FI3782617T3 - Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia - Google Patents
Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia Download PDFInfo
- Publication number
- FI3782617T3 FI3782617T3 FIEP20200070.9T FI20200070T FI3782617T3 FI 3782617 T3 FI3782617 T3 FI 3782617T3 FI 20200070 T FI20200070 T FI 20200070T FI 3782617 T3 FI3782617 T3 FI 3782617T3
- Authority
- FI
- Finland
- Prior art keywords
- gel composition
- inhibitor
- levodopa
- composition according
- pharmaceutical gel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 20
- 239000008252 pharmaceutical gel Substances 0.000 title claims 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title claims 10
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims 10
- 229960004502 levodopa Drugs 0.000 title claims 10
- 229960004205 carbidopa Drugs 0.000 title claims 4
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title claims 4
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title claims 4
- 229960003337 entacapone Drugs 0.000 title claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 22
- 229960003638 dopamine Drugs 0.000 claims 11
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims 7
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 7
- 102000006378 Catechol O-methyltransferase Human genes 0.000 claims 6
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 6
- 239000000499 gel Substances 0.000 claims 6
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344 | 2015-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3782617T3 true FI3782617T3 (fi) | 2024-03-13 |
Family
ID=55440194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20200070.9T FI3782617T3 (fi) | 2014-09-04 | 2015-09-04 | Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10071069B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4356907A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6622310B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107072973A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015312430B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2959307C (cg-RX-API-DMAC7.html) |
| DK (2) | DK3782617T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2844500T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3782617T3 (cg-RX-API-DMAC7.html) |
| HR (2) | HRP20210025T1 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE052857T2 (cg-RX-API-DMAC7.html) |
| PL (2) | PL3782617T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT3188725T (cg-RX-API-DMAC7.html) |
| RS (1) | RS65337B1 (cg-RX-API-DMAC7.html) |
| SI (2) | SI3188725T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016036308A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4356907A1 (en) | 2014-09-04 | 2024-04-24 | LobSor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof |
| WO2016083863A1 (en) * | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| CN107847722B (zh) | 2015-05-06 | 2021-05-18 | 辛纳吉勒公司 | 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| US10874629B2 (en) * | 2016-04-11 | 2020-12-29 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| AU2017299710A1 (en) * | 2016-07-20 | 2019-01-31 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| JP7257322B2 (ja) | 2017-02-13 | 2023-04-13 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | プラドフロキサシンを含有する液体組成物 |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| KR20250043584A (ko) | 2018-03-23 | 2025-03-28 | 롭서 파마슈티컬스 악티에볼라그 | 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여 |
| EP3593819A1 (en) * | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| MX368750B (es) * | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| EP4417258A3 (en) * | 2018-12-18 | 2024-10-30 | Eli Lilly and Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| CA3174918A1 (en) * | 2020-03-13 | 2021-09-16 | Bial - Portela & Ca, S.A. | Micronised opicapone |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| PL4200280T3 (pl) | 2020-10-07 | 2024-05-20 | Eli Lilly And Company | Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1 |
| WO2022158991A1 (en) * | 2021-01-20 | 2022-07-28 | Bial-Portela & Ca., S.A. | Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| EP1135118A1 (en) * | 1998-11-10 | 2001-09-26 | Teva Pharmaceutical Industries Ltd. | Dispersible compositions containing l-dopa ethyl ester |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| WO2005023185A2 (en) | 2003-08-29 | 2005-03-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| CA2653683A1 (en) * | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24-hour intestinal administration of levodopa/carbidopa |
| US8741342B2 (en) | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| PT2252284E (pt) * | 2008-02-06 | 2011-08-23 | Wockhardt Research Center | COMPOSIÇÕES FARMACjUTICAS DE ENTACAPONE, LEVODOPA E CARBIDOPA COM BIODISPONIBILIDADE MELHORADA |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PT2432454T (pt) * | 2009-05-19 | 2017-06-12 | Neuroderm Ltd | Composições para administração contínua de inibidores de dopa decarboxilase |
| HUE047841T2 (hu) | 2010-11-15 | 2020-05-28 | Neuroderm Ltd | L-dopa, dopa dekarboxiláz inhibitorok, katekol-o-metil transzferáz inhibitorok folyamatos adagolására szolgáló készítmények |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| CN105209029A (zh) | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| EP4356907A1 (en) | 2014-09-04 | 2024-04-24 | LobSor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 HR HRP20210025TT patent/HRP20210025T1/hr unknown
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en not_active Ceased
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US12156858B2/en active Active
-
2024
- 2024-10-21 US US18/921,791 patent/US20250041257A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3782617T3 (fi) | Farmaseuttisia geelikoostumuksia, jotka käsittävät levodopaa, karbidopaa ja entakaponia | |
| JP2017527623A5 (cg-RX-API-DMAC7.html) | ||
| PH12019550088A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| AR094936A1 (es) | Suspensión para administración oral que comprende tolvaptán amorfo, y a un método para producirla | |
| MX2021007794A (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| ZA201508924B (en) | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition | |
| PH12017500720A1 (en) | Glycopeptide compositions | |
| JP2015505851A5 (cg-RX-API-DMAC7.html) | ||
| WO2018224689A3 (en) | SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | |
| PH12015502542A1 (en) | Stabilized pemetrexed formulation | |
| MX388073B (es) | Composición farmacéutica, preparación y usos de la misma. | |
| AR092691A1 (es) | Composicion farmaceutica que comprende rebamipida | |
| MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. | |
| WO2019031898A3 (ko) | 약학 조성물 및 이의 제조방법 | |
| PH12014502407B1 (en) | New alfentanil composition for the treatment of acute pain | |
| RU2018101220A (ru) | Продукт на основе хелата бис-глицината железа и альгиновой кислоты и/или ее водорастворимых солей, его составы и его фармацевтические применения | |
| JP2016522257A5 (cg-RX-API-DMAC7.html) | ||
| NZ627991A (en) | Liquid formulations of hypoglycaemic sulphonamides | |
| GR1008308B (el) | Τοπικες φαρμακευτικες και ιατροτεχνολογικες συνθεσεις που περιεχουν συνδυασμους σουκραλφατης, υαλουρονικου οξεος, αργινινης και ενος φυσικου ενυδατικου παραγοντα | |
| JP2019077664A5 (cg-RX-API-DMAC7.html) | ||
| WO2012034659A3 (de) | Pharmazeutische zusammensetzung, enthaltend elektrochemisch aktivierte salzlösung | |
| ZA201906037B (en) | Liquid composition containing pradofloxacin | |
| NZ761073A (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn [patent] |